Skip to content

Psilocybin: all studies

Page 388 of 440: studies 3,871 to 3,880 of 4,392, newest first. Back to the psilocybin overview

Research

Archaeology at the intersection between cognitive neuroscience, performance theory, and architecture: from psychoactive substances to rock art and bone shelters

Time and Mind October 2, 2022 M. R. Lami, Mónica Fernández

We are pleased to present a collection of stimulating research papers that delve into various realms of scientific inquiry, shedding new light on captivating subjects. In this issue, we embark on a journey that spans the enigmatic presence of a mushroom cult in the Southern Levant, ancient divination practices, rock art research, and the symbolic significance of prehistoric architecture. These...

Transforming Psychedelics into Approved Medicines

Genetic Engineering & Biotechnology News October 1, 2022 K. Liszewski

A new model of psilocybin therapy is being developed by Compass Pathways, a mental health company. This model involves the administration of a synthetic psilocybin in conjunction with psychological support in order to treat conditions such as treatment-resistant depression. Most recently, Compass announced the launch of a Phase II trial to investigate the efficacy of its synthetic psilocybin...

Animal Behavior in Psychedelic Research.

Pharmacological Reviews October 1, 2022 Anna U. Odland, Jesper L. Kristensen, Jesper T. Andreasen 23 citations

Psychedelic-assisted psychotherapy holds great promise in the treatment of mental health disorders. Research into 5-hydroxytryptamine 2A receptor (5-HT2AR) agonist psychedelic compounds has increased dramatically over the past two decades. In humans, these compounds produce drastic effects on consciousness, and their therapeutic potential relates to changes in the processing of emotional,...

DOI: 10.1124/pharmrev.122.000590 (opens in new tab) Full text (opens in new tab) Psychedelics Animal-behavior Behavioral-research Therapeutic-compounds

Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos?

Transcultural Psychiatry October 1, 2022 David Dupuis, Samuel P. L. Veissière 70 citations

Following decades of prohibition and widespread concern about their mind-altering properties, there is increasing public, scholarly, and clinical interest in the therapeutic potential of psychedelic substances. Serotonergic substances in particular (DMT, psilocybin, and LSD) are now being tested as treatments for such ailments as depression, anxiety, and substance use disorder. This thematic...

DOI: 10.1177/13634615221131465 (opens in new tab) Enculturation Epistemic authority Suggestibility Psychedelics hallucinogens +7

The use of classic psychedelics among adults: a Danish online survey study

Nordic Journal of Psychiatry September 29, 2022 Tobias Søgaard Juul, Mathias E. Jensen, Anders Fink‐jensen 20 citations

Classic psychedelics were mostly used therapeutically or spiritually and had self-reported positive persisting effects, but were also associated with hazardous use of alcohol, among Danish adults. DMT was associated with significantly greater positive effects compared to LSD and psilocybin.

Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL/6J mice.

Neuroscience Letters September 25, 2022 Alaina M Jaster, Jason Younkin, Travis Cuddy et al. 53 citations

Psychedelics, also known as classical hallucinogens, affect processes related to perception, cognition and sensory processing mostly via the serotonin 5-HT2A receptor (5-HT2AR). This class of psychoactive substances, which includes lysergic acid diethylamide (LSD), psilocybin, mescaline and the substituted amphetamine 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), is receiving renewed...

DOI: 10.1016/j.neulet.2022.136836 (opens in new tab) Full text (opens in new tab) Classical hallucinogens Head-twitch behavior Psychedelics Serotonin 5-ht2a receptor +1

A long trip into the universe: Psychedelics and space travel

Frontiers in Space Technologies September 15, 2022 Leonard Lerer, Jeet Varia 2 citations

Prolonged periods in space have potentially deleterious physiological and psychological effects. Ensuring the physical health and mental well-being of astronauts will inevitably supersede the need for technological innovation, as the major challenge in long-duration space travel. We propose a role for psychedelics (psychoactive fungal, plant, and animal molecules that cause alterations in...

DOI: 10.3389/frspt.2022.899159 (opens in new tab) Consciousness Space punctuation Perception Mood +2

Ketamine Pharmacodynamics Entangled: Reply

Anesthesiology September 12, 2022 Albert Dahan, Erik Olofsen, Thomas K. Henthorn et al. 3 citations

We thank Bowdle et al.1 for their interest in our article,2 and for the important issue they raise, paraphrased as follows: what is the best anthropocentric description of the "mind-altering" effects of a heterogeneous group of compounds and drugs that act at the brain and cause significant changes in mental state. The group of drugs that we are referring to includes N-methyl-d-aspartate (NMDA)...

DOI: 10.1097/aln.0000000000004350 (opens in new tab) Ketamine Pharmacodynamics Pharmacology Anesthesia

Long-term transformative effects and integration challenges of psychedelic experiences

Consciousness, Spirituality & Transpersonal Psychology September 12, 2022 Victor Jivanescu 4 citations

This study looked into the transformative effects and integration challenges of psychedelic experiences with psilocybin and lysergic acid diethylamide (LSD) for the Romanian population. The aim was to determine the long-term transformative effects and challenges individuals might encounter during the integration process. The study employed a sequential mixed method design, using qualitative...

DOI: 10.53074/cstp.2022.29 (opens in new tab) Transformative learning Thematic analysis Interpersonal communication Qualitative property +5

Interest of drug checking supply: Results of 3 years of activity in Geneva

Annales de Toxicologie Analytique September 1, 2022 M. Augsburger, J. Déglon, Christèle Widmer et al.

Aim: Swiss drug policy aims to reduce recreational drug consumption and its negative consequences. The strategy is based on a four pillars concept: prevention, therapy, harm reduction and repression. Among harm reduction programs drug checking (DC) facilities have emerged, allowing drug users to check the presence of adulterants or other non-expected substances, and to gain information...